BioNTech SE reported its full-year 2025 financial results, revealing total revenues of €2.9 billion and a net loss of €1.1 billion. Despite the loss, the biotechnology firm maintains a robust financial foundation with €17.2 billion in cash and security investments. The company is currently undergoing a strategic pivot, shifting its focus from COVID-19 vaccines toward a late-stage oncology pipeline. In a significant leadership update, co-founders Ugur Sahin and Özlem Türeci announced they will establish an independent innovation venture, with a full management transition expected by the end of 2026. This transition marks a new era for the company as it seeks to commercialize its mRNA cancer treatments. Investors are weighing the strong liquidity against the uncertainty surrounding the departure of the company's visionary founders.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis